Stay updated on Amgen Press Releases
Sign up to get notified when there's something new on the Amgen Press Releases page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FsOeHQUcAbzirDWTh9cbqh53pC94.uncropped.jpg&w=3840&q=75)
Latest updates to the Amgen Press Releases page
- ChecktodayChange DetectedIn June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive results for Uplizna® in treating IgG4-related disease and plans to present innovative rheumatology research at EULAR 2024.SummaryDifference100%
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check5 days agoChange DetectedAmgen has made significant advancements, including the FDA approval of Blincyto for B-ALL and Imdelltra for small cell lung cancer, alongside positive trial results for Uplizna in IgG4-RD, while also announcing multiple upcoming presentations at major healthcare conferences.SummaryDifference100%
- Check7 days agoChange DetectedIn June 2024, the FDA approved Blincyto® for treating CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, while Amgen announced positive Phase 3 trial results for Uplizna® and plans to present innovative rheumatology research at EULAR 2024.SummaryDifference100%
- Check8 days agoChange DetectedThe FDA approved Blincyto (blinatumomab) for the treatment of B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, marking a significant advancement in leukemia treatment.SummaryDifference100%
- Check9 days agoChange DetectedFDA approves Blincyto (blinatumomab) in CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, Amgen presents innovative rheumatology research at EULAR 2024, Amgen announces positive results for phase 3 registrational trial evaluating Uplizna (inebilizumab-CDON) for treatment of immunoglobulin G4-related disease (IgG4-RD), New data presented at ATS 2024 show the potential of Tezspire to help patients living with COPD, FDA approves Imdelltra (tarlatamab-dlle), the first and only T-cell engager therapy for the treatment of extensive-stage small cell lung cancer.SummaryDifference100%
- Check12 days agoChange DetectedThe FDA approved Blincyto in the consolidation phase for B-ALL, Amgen presented innovative rheumatology research at EULAR 2024, and positive results were announced for the phase 3 trial of Uplizna for IgG4-RD.SummaryDifference100%
Stay in the know with updates to Amgen Press Releases
Enter your email address, and we'll notify you when there's something new on the Amgen Press Releases page.